Drug Profile
BIA 21
Alternative Names: BIA-21Latest Information Update: 12 Apr 2022
Price :
$50
*
At a glance
- Originator BIAL
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pulmonary arterial hypertension
Most Recent Events
- 12 Apr 2022 BIA 21 is still in preclinical development for Pulmonary-arterial-hypertension in Portugal (BIAL pipeline, April 2022)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in Portugal
- 30 Oct 2017 Preclinical trials in Pulmonary arterial hypertension in Portugal before October 2017 (BIAL pipeline, October 2017)